Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 6,915 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Opioid; Intoxication, Perception Disturbance (Acute), Acute Pain, Overdose of Opiate, Respiratory Depression, Safety Issues
Interventions: Continuous conversational interaction, Remifentanil infusion; Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 20 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Dystonia, Pediatric, Deep Brain Stimulation, Motor Development
Interventions: DBS; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 21 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Spinal Cord Injuries, Paraplegia, Spinal, Tetraplegia/Tetraparesis
Interventions: Transspinal-transcortical paired-associative stimiulation combined with robotic gait training, Transcortical-transspinal paired-associative stimiulation combined with robotic gait training; Device
Lead sponsor: College of Staten Island, the City University of New York; Other
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Anterior Cruciate Ligament Reconstruction, Quadriceps Muscle Weakness, Transcranial Direct Current Stimulation
Interventions: Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional); Device
Lead sponsor: Arcadia University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Glenside, Pennsylvania

Conditions: Pompe Disease
Interventions: Diaphragm conditioning via phrenic nerve stimulation; Other
Lead sponsor: University of Florida; Other
Eligibility: 2 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alzheimer Dementia, Presenile Alzheimer Dementia, Aging
Interventions: Personalized tDCS, Active-Sham; Other
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 65 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Roslindale, Massachusetts

Conditions: Posttraumatic Stress Disorder, Opioid Use Disorder
Interventions: Sparrow Ascent tAN, Sparrow Ascent Active Sham; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cape Girardeau, Missouri

Conditions: Spinal Cord Injuries
Interventions: Open-loop Stimulation, Close-loop Stimulation, Functional Task Practice; Device · Other
Lead sponsor: University of Washington; Other
Eligibility: 21 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Analgesia
Interventions: Naloxone, Saline; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Retinoblastoma
Interventions: subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 10 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 22 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 104
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 77 more

Conditions: Atrial Fibrillation
Interventions: Parasym, Sham stimulation; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 21 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Chemotherapy-induced Neutropenia
Interventions: Plinabulin, Pegfilgrastim; Drug
Lead sponsor: BeyondSpring Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Redlands, California • Orange City, Florida • Dublin, Georgia + 1 more

Conditions: Overactive Bladder
Interventions: Tibial nerve stimulation; Device
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Torrance, California

Conditions: Overactive Bladder
Interventions: Urgent PC Neuromodulation System, Tolterodine; Device · Drug
Lead sponsor: Uroplasty, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minnetonka, Minnesota

Conditions: Adrenal Cortex Diseases, Infant Morbidity
Interventions: Cosyntropin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 365 Days
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Phantom Limb Pain
Interventions: Phantom Motor Execution, Phantom Motor Imagery; Device
Lead sponsor: Integrum; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Effects of Cerebellar Stimulation on Brain Activation
Interventions: TMS during sequence-demanding task, No TMS during sequence-demanding task, TMS during non-sequence-demanding task, No TMS during non-sequence-demanding task; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Behavioral Flexibility, Healthy Volunteers, High Risk Alcohol Use
Interventions: 10 Hz transcranial alternating current stimulation (tACS), sham transcranial alternating current stimulation (tACS); Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 22 Years to 50 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Cytarabine, Filgrastim, Filgrastim-sndz, Fludarabine Phosphate, Laboratory Biomarker Analysis, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Degenerative Cervical Myelopathy
Interventions: Transcutaneous spinal cord stimulation, Balance and Gait Training; Device · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cortical Excitability, Healthy, TMS, Menstrual Cycle, Menopause
Interventions: Transcranial Electrical Stimulation, Transcranial Magnetic Stimulation, TES + TMS; Device
Lead sponsor: Carnegie Mellon University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: filgrastim, therapeutic autologous lymphocytes, cyclophosphamide, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Anxiety, Depression
Interventions: Alpha-Stim Active, Alpha-Stim Inactive; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression

Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia

Transspinal-Transcortical Paired Stimulation for Neuroplasticity and Recovery After SCI

Non-invasive Brain Stimulation to Improve Quadriceps Muscle Function After Anterior Cruciate Ligament Reconstruction

Response to Diaphragmatic Pacing in Subjects With Pompe Disease

Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease

tAN for PTSD and OUD in Buprenorphine Therapy

Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury

RM1 Project 1 - tAN Naloxone

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Synaptic Plasticity in the Epicardial Ganglionated Plexi

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

TTNS vs PTNS in a County Hospital System.

Overactive Bladder Innovative Therapy Trial (OrBIT)

Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery

Phantom Motor Execution Via MPR, VR/AR, and SG, as a Treatment of PLP

Cerebellar Involvement in Cognitive Sequencing

Flexibility, Alcohol Misuse, and Excitation

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stimulation-based Therapy to Improve Balance in DCM

Assessing the Effects of Hormones on Noninvasive Transcranial Stimulation

Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)

Effectiveness of CES on Emotional and Cellular Wellbeing